Wednesday, April 23, 2025 Time: 1:10 p.m. ET Room: 207A Title: Immune profiling on an oral norovirus vaccine candidate; correlates of protection for disease and infection Speaker: Dr. Sean Tucker Date ...

Vaxart ( NASDAQ:VXRT ) Full Year 2024 Results Key Financial Results Revenue: US$28.7m (up 289% from FY 2023). Net loss... Vaxart Inc (VXRT) reports significant revenue growth and strategic ...

Greetings and welcome to the Vaxart Business Update and Fourth Quarter and Full Year 2024 Financial Results Conference call. A question-and-answer session will follow management's opening remarks ...

Oral Vaccine Focused Penny Stock Vaxart Is 'Uniquely Positioned', Analyst Sees Almost 83% Upside Oppenheimer initiates Vaxart coverage with an Outperform rating and $4 price target, citing a ...

Vaxart Inc (NASDAQ:VXRT) shares are trading higher in Monday’s after-hours session after the company provided business and cash runway updates. What Happened: Vaxart, a clinical-stage ...

VAXART ($VXRT) posted quarterly earnings results on Thursday, March 20th. The company reported earnings of -$0.05 per share, beating estimates of -$0.10 by $0.05. The ...

This feature is currently unavailable; we are sorry for the inconvenience to you. Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets ...

Vaxart ( NASDAQ:VXRT ) Full Year 2024 Results Key Financial Results Revenue: US$28.7m (up 289% from FY 2023). Net loss... Vaxart Inc (VXRT) reports significant revenue growth and strategic initiatives ...

SOUTH SAN FRANCISCO, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the “Company” or “Vaxart”) today announced that on March 24, 2025, the independent members of ...

Vaxart ( NASDAQ:VXRT ) Full Year 2024 Results Key Financial Results Revenue: US$28.7m (up 289% from FY 2023). Net loss... Vaxart Inc (VXRT) reports significant revenue growth and strategic initiatives ...